References
- Baniandres O, Rodriguez-Soria VJ, Romero-Jimenez RM, et al. Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting. Actas dermo-sifiliograficas. 2015;106(7):569–577. doi: 10.1016/j.adengl.2015.06.004
- Huang JX, Lee YH, Wei JC. Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis. Int Immunopharmacol. 2023 Feb 8;116:109804. Online ahead of print. doi: 10.1016/j.intimp.2023.109804
- Llamas-Velasco M, Daudén E. Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. Dermatol Ther. 2020;33(6):e14134. doi: 10.1111/dth.14134
- Braverman G, Bridges SL, Moreland LW. Tapering biologic DMARDs in rheumatoid arthritis. Curr Opin Pharmacol. 2022;67:102308. doi: 10.1016/j.coph.2022.102308
- Bagel J, Glick B, Wu JJ, et al. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. J Med Econ. 2021;24(1):782–791. doi: 10.1080/13696998.2021.1937187
- Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J DermatolTreat. 2022 Jun;33(4):2352–2357. doi: 10.1080/09546634.2021.1961998
- Mastorino L, Susca S, Cariti C, et al. “Superresponders” at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors. Exp Dermatol. 2022 Dec 21. doi: 10.1111/exd.14731
- Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9):e049822. doi: 10.1136/bmjopen-2021-049822
- Mehta H, Mashiko S, Angsana J. Differential changes in inflammatory mononuclear phagocyte and T cell profiles within psoriatic skin during treatment with Guselkumab versus Secukinumab. J Invest Dermatol. 2021;141(7):1707–1718.e9. doi: 10.1016/j.jid.2021.01.005
- Schots L, Soenen R, Blanquart B, et al. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):698–710. Epub 2023 Jan 13. PMID: 36562700. doi: 10.1111/jdv.18827